Top Markets
Coin of the day
Inventiva S.A. Inventiva S.A.

Inventiva S.A.

IVA
Ранг среди акций #8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Цена акции
$4.74
Последняя синхронизация: 2026-08-28
Рыночная капитализация
$1.12B
Изменение (1 день)
-5.77%
Изменение (1 год)
-16.96%
Страна
FR
Торговля Inventiva S.A. (IVA)

Категория

Коэффициент P/S для Inventiva S.A. (IVA)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Inventiva S.A., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Inventiva S.A. с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH